IN-VITRO DISSOLUTION STUDY OF MELOXICAM IMMEDIATE RELEASE PRODUCTS USING FLOW THROUGH CELL (USP APPARATUS 4) UNDER DIFFERENT OPERATIONAL CONDITIONS
Keywords:
Flow through cell apparatus, Meloxicam, dissolution, Immediate release, Turbulent flow, Laminar flow, USP Apparatus 4Abstract
Objective: To evaluate and compare the in-vitro dissolution profiles of five generic immediate release (IR) products of Meloxicam (MX) available in Egyptian market with the innovator reference product (Mobic®, R) using different operational conditions of the flow through dissolution cell (FTC, USP Apparatus 4), in phosphate buffer (pH=7.5).
Methods: The comparative in-vitro dissolution studies were performed under different FTC operational conditions such as cell size, tablet position within the cell, open and closed loops setup and type of flow (laminar and turbulent) on MX dissolution rate from different IR products.
Results: The study showed that two generic products, out of five, gave similar dissolution profiles with R using a specified well controlled condition of FTC. A selected generic product (Mobitil, G1) was tested versus R under different operational conditions of the FTC such as cell size, type of flow, tablet position and open & closed loops setup. The dissolution profile of MX from R was highly affected by changing the tablet position, slightly affected by the open & closed loops setup and not affected by cell size and type of flow. On the other hand, the dissolution profile of MX from G1 was affected by all the previous operational conditions. Comparing Æ’2 values between G1 against R among the different operational conditions proposed, only one in-vitro dissolution test showed similar dissolution profile of G1 with respect to R.
Conclusion: Three generic products of MX might not be interchangeable with the innovator product (Mobic®).
Downloads
References
Food and Drug Administration. Guidance for Industry: Extended Release Oral Dosage Forms: Development, Evaluation, and Application of in-vitro/in vivo Correlations; 1997.
Emara L, El-Menshawi B, Estefan M. in-vitro-in vivo correlation and comparative bioavailablity of vincamine in prolonged-release preparations. Drug Dev Ind Pharm 2000;26:243-51.
Jantratid E, De Maio V, Ronda E, Mattavelli V, Vertzoni M, Dressman JB. Application of biorelevant dissolution tests to the prediction of in vivo performance of diclofenac sodium from an oral modified-release pellet dosage form. Eur J Pharm Sci 2009;37:434-41.
Vertzoni M, Dressman J, Butler J, Hempenstall J, Reppas C. Simulation of fasting gastric conditions and its importance for the in vivo dissolution of lipophilic compounds. Eur J Pharm Biopharm 2005;60:413-7.
Food and Drug Administration. Guidance for Industry: Dissolution Testing of Immediate-Release Solid Oral Dosage Forms; 1997.
Shiko G, Gladden L, Sederman A, Connolly P, Butler J. MRI Studies of the hydrodynamics in a usp 4 dissolution testing cell. J Pharm Sci 2011;100:976-91.
Shargel L (Eds.) AT. Pharmacokinetics of Drug Absorption. 2nd ed. Applied Biopharmaceutics and Pharmacokinetics: Appleton-Century-Crofts, Norwalk, CT; 1985.
Moeller H, Langenbuchr F, Porges P, Stricker H, Tucker G. Pharm Ind 1984;46:941-3.
Skelley JP, Amidon GL, Barr WH, Benet LZ, Carter JE, Robinson JR, et al. J Pharm Sci 1990;79:849-54.
Hwang SS, Bayne W, Theeuwes F. In vivo evaluation of controlled-release products. J Pharm Sci 1993;82:1145-50.
Emara LH, Taha NF, Mursi NM. Investigation of the effect of different flow-through cell designs on the release of diclofenac sodium sr tablets. Dissol Technol 2009;16:23-31.
Atyabi F, Koochak M, Dinarvand R. The effect of loading solution and dissolution media on release of diclofenac from ion exchange resins. DARU J Pharm Sci 2002;10:17-22.
Singh I, Aboul-Enein H. Advantages of USP apparatus IV (flow-through cell apparatus) in dissolution studies. J Iran Chem Soc 2006;3:220-2.
Prabhu NB, Marathe AS, Jain S, Singh PP, Sawant K, Rao L, et al. Comparison of dissolution profiles for sustained release resinates of BCS Class I Drugs Using USP Apparatus 2 and 4:A Technical Note. AAPS Pharm Sci Tech 2008;9:769-73.
Emara LH, Abdou AR, El-Ashmawy AA, Badr RM, Taha NF, Mursi NM. In-vitro release evaluation of gastroretentive amoxicillin floating tablets employing a specific design of the flow-through cell. Dissol Technol 2013;20:27-34.
Banaker UV. Pharmaceutical Dissolution Testing. Marcel Dekker, Inc. New York; 1991. p. 322.
Bhattachar SN, Wesley JA, Fioritto A, Martin PJ, Babu SR. Dissolution testing of a poorly soluble compound using the flow-through cell dissolution apparatus. Int J Pharm 2002;236:135-43.
Fotaki N, Reppas C. The flow through cell methodology in the evaluation of intralumenal drug release characteristics. Dissol Technol 2005;12:17-21.
Fotaki N. Flow-Through cell apparatus (usp apparatus 4): operation and features. Dissol Technol 2011;18:46-9.
Vertzoni M. The Development of Biorelevant Dissolution Methods. In JPAG symposium: The Current State of Dissolution Testing; 2008.
Gjellan K, Magnusson A-B, Ahlgren R, Callmer K, Christensen DF, Espmarker U, et al. A collaborative study of the in-vitro dissolution of acetylsalicylic acid gastro-resistant capsules comparing the flow-through cell method with the USP paddle method. Int J Pharm 1997;151:81-90.
Dressman J, Vertzoni M, Goumas K, Reppas C. Estimating drug solubility in the gastrointestinal tract. Adv Drug Deliver Rev 2007;59:591-602.
Qiu S, Ke Wang, Li M. In-vitro dissolution studies of immediate release and extended release formulations using flow-through cell apparatus. Dissol Technol 2014;4:6-15.
Zhang G, Vadino W, Yang T, Cho W, Chaudry I. Evaluation of the flow-through cell dissolution apparatus: effects of flow rate, glass beads and tablet position on drug release from different type of tablets. Drug Dev Ind Pharm 1994;20:2063-78.
Saleh S, Khider S, Beyssac E, Camacho R. Comparative dissolution profiles of five internationally-available sustained-release diclofenac dosage forms. STP Pharm Sci 1992;2:242-6.
Cammarn SR, Sakr A. Predicting dissolution via hydrodynamics: salicylic acid tablets in flow through cell dissolution. Int J Pharm 2000;201:199-209.
Bielen N. Performance of USP calibrator tablets in flow-through cell apparatus. Int J Pharm 2002;233:123-9.
Morihara M, Aoyagi N, Kaniwa N, Katori N, Kojim S. Hydrodynamic flows around tablets in different pharmacopeial dissolution tests. Drug Dev Ind Pharm 2002;28:655-62.
Emara LH, Abdou AR, EL-Ashmawy AA, Badr RM, Mursi NM. In-vitro evaluation of floating matrix tablets of amoxicillin and metronidazole for the eradication of helicobacter pylori. Int J Pharm Pharm Sci 2012;4.
ParojÄić J, Vasiljević D, Ibrić S, Djurić Z. Tablet disintegration and drug dissolution in viscous media: paracetamol ir tablets. Int J Pharm 2008;355:93-9.
United State Pharmacopeia and National Formulary USP 32-NF 27;The United States Pharmacopeial Convention, Inc: Rockville MD; 2009.
Moore JW, Flanner HH. Mathematical comparison of dissolution profiles. Pharm Technol 1996;20:64-74.
Shah VP, Tsong Y, Sathe P, Liu JP. In-vitro dissolution profile comparison—statistics and analysis of the similarity factor f2. Pharm Res 1998;15:889-96.
Khan K, Rhodes CT. Effect of compaction pressure on the dissolution efficiency of some direct compression systems. Pharm Acta Helv 1972;47:594-607.
Ngwuluka N, Lawal K, Olorunfemi P, Ochekpe N. Post-market In-vitro bioequivalence study of six brands of ciprofloxacin tablets/caplets in jos, nigeria. Sci Res Essay 2009;4:298-305.
Anderson N, Bauer M, Boussac N, Khan-Malek R, Munden P, Sardaro M. An evaluation of fit factors and dissolution efficiency for the comparison of in-vitro dissolution profiles. J Pharm Biomed Anal 1998;17:811-22.
Tsubouchi Y, Sano H, Yamada R, Hashiramoto A, Kohno M, Kusaka Y, et al. Preferential inhibition of cyclooxygenase-2 by meloxicam in human rheumatoid synoviocytes. Eur J Pharmacol 2000;395:255-63.
Pomázi A, Ambrus R, Sipos P, Szabó-Révész P. Analysis of co-spray-dried meloxicam–mannitol systems containing crystalline microcomposites. J Pharm Biomed Anal 2011;56:183-90.
Luger P, Daneck K, Engel W, Trummlitz G, Wagner K. Structure and physicochemical properties of meloxicam, a new NSAID. Eur J Pharm Sci 1996;4:175-87.
Gao C, Huang J, Jiao Y, Shan L, Liu Y, Li Y, et al. In-vitro release and in vivo absorption in beagle dogs of meloxicam from eudragit® fs 30 d-coated pellets. Int J Pharm 2006;322:104-12.
Hanft G, Türck D, Scheuerer S, Sigmund R. Meloxicam oral suspension: a treatment alternative to solid meloxicam formulations. J Inflamm Res 2001;50:35-7.
Han H-K, Choi H-K. Improved absorption of meloxicam via salt formation with ethanolamines. Eur J Pharm Biopharm 2007;65:99-103.
Brown W. Apparatus 4 flow tthrough cell: some thoughts on operational characteristics. Dissol Technol 2005;30:5-28.
Emara LH, Taha NF, El-Ashmawy AA, Raslan HM, Mursi NM. A rapid and sensitive bioanalytical hplc method for determining diclofenac sodium in human plasma for bioequivalence studies. J Liq Chrom Rel Technol 2012;35:2203-16.
Badr RM. Improvement of Nifidepine Bioavailability in Oral Drug Delivery Systems. Phd Thesis, Cairo University; 2006.
Wu Y, Ghaly ES. Effect of hydrodynamic environment on tablet dissolution using flow-through dissolution apparatus. P R Health Sci J 2006;25.
Grewe N, Steglich F. Handbook on the Physics and Chemistry of Rare Earths. Vol. 14. Amsterdam: Elsevier; 1991. p. 343.